Which is the best strategy for diagnosing bronchial carcinoid tumours? The role of dual tracer PET/CT scan.

Details

Serval ID
serval:BIB_05930EA9E362
Type
Article: article from journal or magazin.
Publication sub-type
Editorial
Collection
Publications
Title
Which is the best strategy for diagnosing bronchial carcinoid tumours? The role of dual tracer PET/CT scan.
Journal
Hellenic journal of nuclear medicine
Author(s)
Lococo F., Treglia G.
ISSN
1790-5427 (Print)
ISSN-L
1790-5427
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
17
Number
1
Pages
7-9
Language
english
Notes
Publication types: Editorial
Publication Status: ppublish
Abstract
Bronchial carcinoids (BC) are rare well-differentiated neuroendocrine tumours (NET) sub-classified into typical (TC) and atypical carcinoids (AC). A correct pathological identification in the pre-operative setting is a key element for planning the best strategy of care, considering the different biological behavior of TC and AC. Controversial results have been reported on the diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in BC. On the other hand, there is increasing evidence supporting the use of PET with somatostatin analogues (dotanoc, dotatoc or dotatate) labeled with gallium-68 ((68)Ga) in pulmonary NET. Based on information obtained by using different radiopharmaceuticals and different (68)Ga labeled somatostatin analogues in PET and PET/CT studies, we are able to diagnose BC. In conclusion, by using somatostatin receptor imaging and (18)F-FDG PET/CT scan, we can differentiate BC from benign pulmonary lesions and TC from AC by specific diagnostic patterns. Clinical trials on larger groups of patient would allow for a better and "tailored" therapeutic strategy in NET patients using dual-tracer PET/CT to identify BC and distinguish between TC and AC.

Pubmed
Web of science
Create date
20/08/2017 18:36
Last modification date
20/08/2019 12:27
Usage data